Cardiac sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cardiac sarcoidosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Testing the Accuracy of 68Ga-Pentixafor PET/CT Imaging in Patients with Cardiac Sarcoidosis https://clinicaltrials.eu/trial/a-study-testing-the-accuracy-of-68ga-pentixafor-pet-ct-imaging-in-patients-with-cardiac-sarcoidosis/ Thu, 30 Apr 2026 13:08:42 +0000 https://clinicaltrials.eu/trial/a-study-testing-the-accuracy-of-68ga-pentixafor-pet-ct-imaging-in-patients-with-cardiac-sarcoidosis/ This study is looking at cardiac sarcoidosis, which is a condition where small collections of inflammatory cells form in the heart muscle. Sarcoidosis is a disease that can affect different parts of the body, and when it involves the heart, it can cause problems with how the heart works. The study will use a substance called [68Ga]Ga-PentixaFor, which is given as an injection into a vein. This substance contains gallium-68 and pentixafor, and it is used together with a special imaging test called positron emission tomography combined with computed tomography, or PET/CT for short. This imaging method creates detailed pictures of the inside of the body and can help doctors see areas of inflammation in the heart.

The purpose of the study is to check how well 68Ga-Pentixafor PET/CT can detect cardiac sarcoidosis. The results from this new scan will be compared to another scan called 18F-FDG PET/CT, which is already used in regular medical practice to look for this condition. The study will involve patients who have sarcoidosis in other parts of their body and who are suspected of having or already have cardiac sarcoidosis. These patients will receive the 68Ga-Pentixafor injection and undergo the PET/CT scan in addition to their regular 18F-FDG scan.

During the study, doctors will look at the scan images to see if and where the 68Ga-Pentixafor is taken up in the heart muscle. They will measure how much of the substance appears in different areas and describe the pattern of uptake, whether it appears in small spots or spread throughout the heart. The images will be examined by experienced doctors who will compare their findings. The study will also check if the substance shows up in other organs that might be affected by sarcoidosis and will look at how the substance moves through the body over time.

]]> Detecting Heart Inflammation in Cardiac Sarcoidosis Patients Using 68Ga-NOTA-Anti-MMR-VHH2 PET-CT Imaging https://clinicaltrials.eu/trial/detecting-heart-inflammation-in-cardiac-sarcoidosis-patients-using-68ga-nota-anti-mmr-vhh2-pet-ct-imaging/ Wed, 29 Apr 2026 14:59:04 +0000 https://clinicaltrials.eu/trial/detecting-heart-inflammation-in-cardiac-sarcoidosis-patients-using-68ga-nota-anti-mmr-vhh2-pet-ct-imaging/ This clinical trial is focused on studying cardiac sarcoidosis, a condition where clusters of inflammatory cells form in the heart tissue. The study will use a new imaging method involving a tracer called 68Ga-NOTA-Anti-MMR-VHH2. This tracer is a special solution that is injected into the body and helps to highlight certain cells in the heart when scanned with a type of imaging called PET-CT (Positron Emission Tomography – Computed Tomography). The purpose of the study is to see if this new tracer can effectively detect areas of inflammation in the heart caused by cardiac sarcoidosis.

Participants in the study will receive an injection of the tracer 68Ga-NOTA-Anti-MMR-VHH2 and then undergo a PET-CT scan. This scan will help doctors see if there are any areas in the heart where the tracer has accumulated, indicating inflammation. The study will compare these results with previous standard imaging tests to determine the effectiveness of the new tracer. Some participants may also receive a placebo for comparison purposes.

The study will monitor participants for any side effects or reactions to the tracer. It will also compare the new imaging results with other tests to see how well the tracer works in identifying inflammation related to cardiac sarcoidosis. The study aims to improve the detection and understanding of this condition, potentially leading to better diagnosis and treatment options in the future.

]]>